Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM)

Date: 
6 Nov 2017
Source: 
NCRI
Audience: 
Professionals
Type of resource: 
Research

Olaparib, a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), may improve GBM outcomes by enhancing the cytotoxic effects of ionising radiation and TMZ. Clinical development of PARP inhibitors in combination with chemotherapy has been restricted by exacerbation of haematological toxicity. We investigated tumour pharmacokinetics (PK) of olaparib and safety and tolerability of its combination with TMZ.

 

Click here to read the Research article in full